| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.12M | 6.77M | 5.27M | 4.27M | 4.13M | 4.59M |
| Gross Profit | 5.70M | 5.60M | 4.12M | 3.32M | 3.45M | 4.15M |
| EBITDA | -497.83K | 350.00K | -3.22M | -989.00K | -1.29M | -3.72M |
| Net Income | -1.65M | -1.29M | -4.62M | -3.10M | -3.33M | -5.88M |
Balance Sheet | ||||||
| Total Assets | 8.13M | 7.40M | 7.81M | 11.15M | 14.20M | 12.59M |
| Cash, Cash Equivalents and Short-Term Investments | 1.36M | 1.03M | 886.00K | 1.90M | 5.36M | 1.97M |
| Total Debt | 5.31M | 5.06M | 4.65M | 3.59M | 3.66M | 3.77M |
| Total Liabilities | 10.33M | 9.63M | 8.91M | 7.97M | 7.49M | 7.64M |
| Stockholders Equity | -2.20M | -2.23M | -1.10M | 3.18M | 6.71M | 4.95M |
Cash Flow | ||||||
| Free Cash Flow | 1.80M | 268.00K | -2.00M | -2.97M | -802.00K | -1.90M |
| Operating Cash Flow | 1.80M | 1.42M | -879.00K | -2.12M | -47.00K | -942.00K |
| Investing Cash Flow | -1.06M | -1.16M | -1.16M | -848.00K | -755.00K | -961.00K |
| Financing Cash Flow | -3.00K | -122.00K | 1.04M | -535.00K | 4.19M | 2.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £55.84M | 13.14 | 11.39% | ― | 9.90% | 37.20% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
52 Neutral | £15.52M | -5.79 | -14.80% | ― | 30.40% | 23.48% | |
48 Neutral | £22.24M | -8.19 | ― | ― | 15.59% | 54.47% | |
44 Neutral | $29.69M | -0.88 | -47.36% | 3.45% | ― | ― |
KRM22 reported that for the year to 31 December 2025 it achieved annual recurring revenue of £7.6m, up 19% at constant exchange rates, driven largely by £1.6m of new contracted ARR from cross-sales and price increases across its Risk Manager, Limits Manager and Market Surveillance applications, partially offset by modest churn linked to product switching by two institutional clients. Total revenue rose 11% to about £7.5m, while adjusted EBITDA slipped to £0.7m, but the group’s balance sheet was transformed by a £9.2m equity raise in November that left it debt-free and with £5.2m of year-end cash, positioning management to pursue its growth strategy, invest in sales, marketing and product development, and expand its risk management suite into multi-asset solutions for capital markets clients without the constraints of heavy leverage or restrictive covenants.
The most recent analyst rating on (GB:KRM) stock is a Hold with a £38.00 price target. To see the full list of analyst forecasts on KRM22 stock, see the GB:KRM Stock Forecast page.
KRM22 has appointed seasoned fintech executive Justin Llewellyn-Jones as a Non-Executive Director, effective 7 January 2026, adding more than 30 years of experience across multi-asset trading, product development and operational strategy in futures, options, FX, fixed income and compliance technology. Currently CEO of Trading Technologies and formerly a senior leader at Broadridge, ION and Fidessa, Llewellyn-Jones is expected to bolster KRM22’s push to expand its suite of risk management applications into multi-asset solutions for the capital markets industry, supporting the company’s next phase of growth and strengthening its board-level industry expertise.
The most recent analyst rating on (GB:KRM) stock is a Hold with a £39.00 price target. To see the full list of analyst forecasts on KRM22 stock, see the GB:KRM Stock Forecast page.
KRM22 plc has issued 46,729 new ordinary shares to partially satisfy deferred consideration for its acquisition of Object+. This move aims to conserve cash within the company while maintaining its financial commitments. The new shares, representing 0.1% of the issued share capital, are expected to commence trading on AIM on 14 November 2025. This strategic decision reflects KRM22’s ongoing efforts to manage its resources effectively and maintain its market position in the risk management sector.
The most recent analyst rating on (GB:KRM) stock is a Hold with a £41.00 price target. To see the full list of analyst forecasts on KRM22 stock, see the GB:KRM Stock Forecast page.